The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.
 
John H. Strickler
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Chengdu Kanghong Biotech; Genentech/Roche; Mereo Biopharma; Natera (Inst); OncoMed; Pfizer; Proteus Digital Health; Seagen (Inst)
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Curegenix (Inst); Exelixis (Inst); Gilead Sciences (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Nektar (Inst); OncoMed (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Seagen
 
Yoshiaki Nakamura
Research Funding - Genomedia (Inst); Guardant Health (Inst); Taiho Pharmaceutical (Inst)
 
Takayuki Yoshino
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Daniel V.T. Catenacci
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Imugene; Jounce Therapeutics; Lilly; Merck; Merck Serono; Merck Sharpe and Dohme Corp.; Michael J. Hennessy Associates; Ono Pharmaceutical; Paradigm; Peerview; Pfizer; Physicans' Education Resource; Rgenix; Seagen; Zymeworks
Research Funding - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Lilly; Merck; Rgenix (Inst); Roche
 
Afsaneh Barzi
Leadership - Cardiff Oncology
Consulting or Advisory Role - Bayer Technology System; bioTheranostics; Merrion
Research Funding - Bayer (Inst); Merck (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Bayer (Inst); Celgene (Inst); Immuneering; Imugene; Incyte (Inst); Ipsen (Inst); Lilly (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - ARMO BioSciences; AstraZeneca; Exelixis; Lilly; Merck (Inst); Sillajen
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Isofol Medical; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono
 
Jeeyun Lee
Consulting or Advisory Role - Oncologie; Seagen
Research Funding - AstraZeneca; Lilly; Merck Sharp & Dohme
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Hyun Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
MARIA ALSINA
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; MSD Oncology; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; Lilly; Roche/Genentech
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; CheckmAb; Clovis Oncology; Daiichi Sankyo; Incyte; Merck; Novartis; Roche/Genentech; Seagen
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Joal Garrido Mayor
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Maria Corinna Palanca-Wessels
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Wentao Feng
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
John Marshall
Employment - Caris Life Sciences; Indivumed
Honoraria - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Merck; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Taiho Pharmaceutical
Speakers' Bureau - Amgen; Bayer/Onyx; Celgene; Genentech/Roche; Merck; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Genentech/Roche (Inst); MedImmune (Inst); Pfizer (Inst)